Merck Expands Keytruda Trial Collaboration With Amgen, Unveils Others
This article was originally published in The Pink Sheet Daily
Merck’s sBLA for Keytruda in lung cancer has been accepted by FDA and granted an Oct. 2 action date, the firm announced. The company also revealed several new research collaborations to study Keytruda in more combination trials at ASCO.
Register for our free email digests: